Cardiac implantable electronic and other monitoring devices in continuous-flow left ventricular assist device patients. A clinical consensus statement of the Heart Failure Association and the European Heart Rhythm Association of the ESC

Author(s):
Amir, O.; Adamopoulos, S.; Burri, H.; Bayes-Genis, A.; Leclercq, C.; Cikes, M.; Egorova, A.; Peichl, P.; Fudim, M.; Rao, A.R.A.; Gustafsson, F.; Richter, S.; Pagnesi, M.; Rosano, G.; Ruschitzka, F.; Nielsen, J.C.
Published
2025
Publication type
Article / Letter to editor

Abstract

The management of heart failure patients with continuous-flow left ventricular assist device (LVAD) patients is challenging. While one third of these patients are recipients of cardiac implantable electronic devices (CIEDs), the risk for atrial and ventricular arrhythmias may coexist. The lack of large datasets and dedicated randomized controlled trials (RCTs) focusing on LVAD and CIED implantation and management has brought medical centres to develop their own protocols and guidelines. This clinical consensus statement of the Heart Failure Association and the European Heart Rhythm Association of the ESC is a joint effort to summarize the current literature and provide advice on patient management within this field.

Left ventricular assist deviceCardiac implantable electronic devicePacemakerCardiac resynchronization therapyRemote monitoring
Date issued
2025-04-01
Language
English
Publisher
WILEY
Is part of
European Journal of Heart Failure (2025), Vol. 27, no. 5, p. 808-821
hdl
1887/4300318
doi
10.1002/ejhf.3635